ALXN - Alexion Pharmaceuticals, Inc.
112.00 -0.43 (-0.38%)
Pre-Market: 7:00AM EST
| Previous Close | 117.01 |
| Open | 117.27 |
| Bid | 108.83 x 900 |
| Ask | 112.47 x 800 |
| Day's Range | 112.33 - 118.20 |
| 52 Week Range | 102.10 - 140.77 |
| Volume | 2,560,658 |
| Avg. Volume | 1,613,246 |
| Market Cap | 25.083B |
| Beta (3Y Monthly) | 1.12 |
| PE Ratio (TTM) | 164.13 |
| EPS (TTM) | 0.69 |
| Earnings Date | Feb 6, 2019 - Feb 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 164.35 |
Market Realist•2 days agoWhy Neurocrine Biosciences Stock Is Plummeting Today
Today, Neurocrine Biosciences (NBIX) is trading at $67.91, a ~20.83% fall from its closing price of $85.76 on December 11. Neurocrine stock has hit its 52-week low of $64.72. Neurocrine stock was trading at $103.0 at the close of market on November 12, and it reached $85.69 on December 11, representing a ~17% fall in the month.
Zacks•2 days agoThe Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen
The Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen
- Zacks•3 days ago
4 Biotech Stocks Investors Can Add to Their Portfolio in 2019
Year 2018 so far has been tough for the biotech sector. Let us take a look at four stocks that can be compelling choices for 2019.
- Zacks•3 days ago
Abeona Therapeutics (ABEO) in Focus: Stock Moves 5.5% Higher
Abeona Therapeutics (ABEO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Markit•3 days agoSee what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.
Alexion Pharmaceuticals Inc NASDAQ/NGS:ALXN
- Zacks•4 days ago
Clovis Oncology (CLVS) in Focus: Stock Moves 6.9% Higher
Clovis Oncology (CLVS) shares rose nearly 7% in the last trading session, amid huge volumes.
Zacks•4 days ago5 Top Drug/Biotech Merger & Acquisition Targets for 2019
Here are five stocks that are attractive and most likely to be takeout targets in 2019.
- Insider Monkey•4 days ago
Should You Avoid Alexion Pharmaceuticals, Inc. (ALXN)?
Investing in hedge funds can bring large profits, but it’s not for everybody, since hedge funds are available only for high-net-worth individuals. They generate significant returns for investors to justify their large fees and they allocate a lot of time and employ a complex analysis to determine the best stocks to invest in. A particularly […]
- Zacks•9 days ago
Inovio (INO) to Receive Milestone Payment From AstraZeneca
Inovio (INO) to receive an undeclared milestone amount from AstraZeneca following the initiation of dosing in a phase II combo inspection of the latter's MEDI0457 for treating HPV-related cancers.
- Zacks•9 days ago
UNITY (UBX) Soars: Stock Adds 5.1% in Session
UNITY (UBX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
- Zacks•9 days ago
Should You Get Rid of Acadia Healthcare (ACHC) Now?
Acadia Healthcare (ACHC) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
- Zacks•10 days ago
Amgen's BiTE Immunotherapies Show Promise in Early Studies
Amgen's (AMGN) BiTE immunotherapy candidates, namely AMG 420 and AMG 330 show positive results in early-stage studies. AMG 420 gets a fast track designation from the FDA
- Zacks•10 days ago
Global Blood Therapeutics' Voxelotor on Faster Approval Path
Global Blood Therapeutics (GBT) announces FDA nod for an accelerated approval pathway for voxelotor as a treatment for sickle cell disease. Stock rallies.
Markit•10 days agoSee what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.
Alexion Pharmaceuticals Inc NASDAQ/NGS:ALXN
- Business Wire•11 days ago
Comprehensive Positive Phase 3 Data for Alexion’s ALXN1210 in Patients with Paroxysmal Nocturnal Hemoglobinuria Presented at American Society of Hematology (ASH) Annual Meeting and Published in Blood
- First Conference Presentation of Results for ALXN1210 in Patients on Soliris® at ASH -
- Zacks•11 days ago
FDA Committee to Review Amgen's (AMGN) Osteoporosis Candidate
The FDA's BRUDAC committee will review Amgen (AMGN) and its European partner UCB's BLA for Evenity so that the candidate gets approved for treating osteoporosis in postmenopausal women.
- Zacks•11 days ago
Fate Therapeutics (FATE) Jumps: Stock Rises 8.9%
Fate Therapeutics (FATE) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
- Zacks•14 days ago
Why Immunomedics (IMMU) Could Be Positioned for a Slump
Immunomedics (IMMU) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Market Realist•15 days agoHow BioMarin Pharmaceutical’s Financials Look in November
BioMarin Pharmaceutical’s (BMRN) net revenues over the first nine months of this year amounted to $1.1 billion compared to $955.3 million in the same period the prior year, a ~19% YoY increase. BioMarin Pharmaceutical reported net revenues of $391.7 million in the third quarter, which reflected ~17% YoY growth.
Market Realist•15 days agoWall Street Analysts Are Mostly Positive on BioMarin
BioMarin Pharmaceutical’s net income and EPS for the first nine months of this year amounted to -$73.6 million and -$0.42, respectively, compared to -$65.7 million and -$0.38 in the same period the prior year.
- Zacks•16 days ago
Aileron Inks Collaboration Deal With Pfizer for Cancer Combo
Aileron Therapeutics (ALRN) signs a clinical trial collaboration contract with Pfizer to study the combo of Aileron's ALRN-6924 and Pfizer's Ibrance for treating MDM2-amplified cancers. Stock rises.
- Zacks•17 days ago
Eyenovia Initiates Phase III Study for Mydriasis Candidate
Eyenovia (EYEN) starts enrollment in the first phase III study of a two clinical study program to evaluate its mydriasis candidate, MicroStat. Stock rallies.
- Zacks•17 days ago
Rocket Pharmaceuticals (RCKT) in Focus: Stock Moves 7.2% Higher
Rocket Pharmaceuticals (RCKT) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Markit•17 days agoSee what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.
Alexion Pharmaceuticals Inc NASDAQ/NGS:ALXN
